In treating a subgroup of HFpatients with canakinumab, we also found the same positive results in both humanand animal studies, even though the CANTOS trial was not designed solely to testthe effectiveness of IL-1β-targeted therapy for HF. This evidence concerns the gene IL1B and hydrops fetalis.